VISCHER has advised TargImmune on the deal.TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused on…
VISCHER has advised TargImmune on the deal.TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused on…
You must be a Standard 1 Year member to access this content.
…
You must be a Standard 1 Year member to access this content.